SEARCH

SEARCH BY CITATION

References

  • Alzuherri, H. , McGilvray, R. , Kilbey, A. & Bartholomew, C. (2006) Conservation and expression of a novel alternatively spliced Evi1 exon. Gene, 384, 154162.
  • Aytekin, M. , Vinatzer, U. , Musteanu, M. , Raynaud, S. & Wieser, R. (2005) Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5′-ends. Gene, 15, 160168.
  • Barjesteh van Waalwijk van Doorn-Khosrovani, S. , Erpelinck, C. , van Putten, W.L. , Valk, P.J. , van der Poel-van de Luytgaarde, S. , Hack, R. , Slater, R. , Smit, E.M. , Beverloo, H.B. , Verhoef, G. , Verdonck, L.F. , Ossenkoppele, G.J. , Sonneveld, P. , de Greef, G.E. , Löwenberg, B. & Delwel, R. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood, 101, 837845.
  • Bartholomew, C. , Kilbey, A. , Clark, A.M. & Walker, M. (1997) The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene, 14, 569577.
  • Ben-Neriah, Y. , Daley, G.Q. , Mes-Masson, A.M. , Witte, O.N. & Baltimore, D. (1986) The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 85, 212214.
  • Bianchini, M. , Martinelli, G. , Renzulli, M. , Gonzalez Cid, M. & Larripa, I. (2007) cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib. Cancer Chemotherapy and Pharmacology, 59, 349360.
  • Carapeti, M. , Goldman, J.M. & Cross, N.C. (1996) Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia. Leukemia, 10, 1561.
  • Carlesso, N. , Frank, D. & Griffin, J.D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. The Journal of Experimental Medicine, 183, 811820.
  • Daghistani, M. , Marin, D. , Khorashad, J.S. , Wang, L. , May, P.C. , Palliompeis, C. , Milojkovic, D. , De Melo, V.A. , Gerrard, G. , Goldman, J.M. , Apperley, J.F. , Clark, R.E. , Foroni, L. & Reid, A.G. (2010) EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-gneration tyrosine kinase inhibitors. Blood, 116, 60146017.
  • De Weer, A. , Poppe, B. , Cauwelier, B. , Carlier, A. , Dierick, J. , Verhasselt, B. , Philippé, J. , Van Roy, N. & Speleman, F. (2008) EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22). BMC Cancer, 8, 193.
  • Elrick, L.J. , Jørgensen, H.G. , Mountford, J.C. & Holyoake, T.L. (2005) Punish the parent not the progeny. Blood, 105(5), 18621866.
  • Fabbro, D. , Buchdunger, E. , Wood, J. , Mestan, J. , Hofmann, F. , Ferrari, S. , Mett, H. , O'Reilly, T. & Meyer, T. (1999) Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacology and Therapeutics, 82, 293301.
  • Fears, S. , Mathieu, C. , Zeleznik-Le, N. , Huang, S. , Rowley, J.D. & Nucifora, G. (1996) Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proceedings of the National Academy of Sciences of the United States of America, 93, 16421647.
  • Gerhardt, T.M. , Schmahl, G.E. , Flotho, C. , Rath, A.V. & Niemeyer, C.M. (1997) Expression of the Evi-1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors. British Journal Haematology, 99, 882887.
  • Goyama, S. , Yamamoto, G. , Shimabe, M. , Sato, T. , Ichikawa, M. , Ogawa, S. , Chiba, S. & Kurokawa, M. (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell, 3, 207220.
  • Håkansson, P. , Nilsson, B. , Andersson, A. , Lassen, C. , Gullberg, U. & Fioretos, T. (2008) Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosomes Cancer, 47, 267275.
  • Hamilton, A. , Gallipoli, P. , Nicholson, E. & Holyoake, T.L. (2010) Targeted therapy in haematological malignancies. Journal of Pathology, 220, 404418.
  • Henzan, H. , Yoshimoto, G. , Okeda, A. , Nagasaki, Y. , Hirano, G. , Takase, K. , Tanimoto, T. , Miyamoto, T. , Fukuda, T. , Nagafuji, K. & Harada, M. (2004) Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia. Annals of Hematology, 83, 784788.
  • Hoyt, P.R. , Bartholomew, C. , Davis, A.J. , Yutzey, K. , Gamer, L.W. , Potter, S.S. , Ihle, J.N. & Mucenski, M.L. (1997) The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mechanisms of Development, 65, 5570.
  • Huang, S. (1999) The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Frontiers in bioscience, 4, D528D532.
  • Irvine, D.A. , Heaney, N.B. & Holyoake, T.L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors–a synthesis of clinical and laboratory data. Blood Reviews, 24, 19.
  • Jørgensen, H.G. , Allan, E.K. , Graham, S.M. , Godden, J.L. , Richmond, L. , Elliott, M.A. , Mountford, J.C. , Eaves, C.J. & Holyoake, T.L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19, 11841191.
  • Khanna-Gupta, A. , Lopingco, M.C. , Savinelli, T. , Zibello, T. , Berliner, N. & Perkins, A.S. (1996) Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3. Oncogene, 12, 563569.
  • Kilbey, A. & Bartholomew, C. (1998) Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts. Oncogene, 16, 22872291.
  • Konopka, J.B. , Watanabe, S.M. & Witte, O.N. (1984) An alteration of the human c-abl protein in K562 leukaemia cells unmasks associated tyrosine kinase activity. Cell, 37, 10351042.
  • Kurzrock, R. , Gutterman, J.U. & Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome positive leukaemias. New England Journal of Medicine, 319, 990998.
  • Kustikova, O. , Fehse, B. , Modlich, U. , Yang, M. , Düllmann, J. , Kamino, K. , von Neuhoff, N. , Schlegelberger, B. , Li, Z. & Baum, C. (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science, 308, 11711174.
  • Lin, P. , Lennon, P.A. , Yin, C.C. & Abruzzo, L.V. (2009) Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24). Cancer Genetics and Cytogenetics, 193, 119122.
  • Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods, 25, 402408.
  • Lugthart, S. , van Drunen, E. , van Norden, Y. , van Hoven, A. , Erpelinck, C.A. , Valk, P.J. , Beverloo, H.B. , Löwenberg, B. & Delwel, R. (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 over expression and chromsome 3q26 abnormalities underestimated. Blood, 111, 43294337.
  • Lugthart, S. , Figueroa, M.E. , Bindels, E. , Skrabanek, L. , Valk, P.J.M. , Li, Y. , Meyer, S. , Erpelinck-Verschueren, C. , Greally, J. , Löwenberg, B. , Melnick, A. & Delwel, R. (2011) Aberrant DNA hypermethylation signature in acute myeloid leukaemia directed by EVI1. Blood, 117, 234241.
  • Melo, J.V. & Barnes, D.J. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer, 7, 441453.
  • Mitani, K. , Ogawa, S. , Tanaka, T. , Miyoshi, H. , Kurokawa, M. , Mano, H. , Yazaki, Y. , Ohki, M. & Hirai, H. (1994) Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO Journal, 13, 504510.
  • Morishita, K. , Parker, D.S. , Mucenski, M.L. , Jenkins, N.A. , Copeland, N.G. & Ihle, J.N. (1988) Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell, 54, 831840.
  • Morishita, K. , Parganas, E. , Douglass, E.C. & Ihle, J.N. (1990a) Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene, 5, 963971.
  • Morishita, K. , Parganas, E. , Bartholomew, C. , Sacchi, N. , Valentine, M.B. , Raimondi, S.C. , Le Beau, M.M. & Ihle, J.N. (1990b) The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t(3;5)(q25;q34) translocations. Oncogene Research, 5, 221231.
  • Morishita, K. , Parganas, E. , William, C.L. , Whittaker, M.H. , Drabkin, H. , Oval, J. , Taetle, R. , Valentine, M.B. & Ihle, J.N. (1992) Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proceedings of the National Academy of Sciences of the United States of America, 89, 39373941.
  • Nakamura, Y. , Nakazato, H. , Sato, Y. , Furusawa, S. & Mitani, K. (2002) Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). American Journal of Hematology, 69, 8082.
  • Nunoda, K. , Tauchi, T. , Takaku, T. , Okabe, S. , Akahane, D. , Sashida, G. , Ohyashiki, J.H. & Ohyashiki, K. (2007) Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene, 26, 41794188.
  • Ogawa, S. , Kurokawa, M. , Tanaka, T. , Tanaka, K. , Hangaishi, A. , Mitani, K. , Kamada, N. , Yazaki, Y. & Hirai, H. (1996) Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia, 10, 788794.
  • O'Hare, T. , Corbin, A.S. & Druker, B.J. (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Current Opinion in Genetics and Development, 16, 9299.
  • Paquette, R.L. , Nicoll, J. , Chalukya, M. , Elashoff, D. , Shah, N.P. , Sawyers, C. , Spiteri, E. , Nanangud, G. & Rao, P.N. (2011) Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genetics, 204, 392397.
  • Pendergast, A.M. , Quilliam, L.A. , Cripe, L.D. , Bassing, C.H. , Dai, Z. , Li, N. , Batzer, A. , Rabun, K.M. , Der, C.J. , Schlessinger, J. & Gishizky, M.L. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 75, 175185.
  • Russell, M. , Thompson, F. , Spier, C. & Taetle, R. (1993) Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. Leukemia, 7, 16541657.
  • Sellers, S. , Gomes, T.J. , Larochelle, A. , Lopez, R. , Adler, R. , Krouse, A. , Donahue, R.E. , Childs, R.W. & Dunbar, C.E. (2010) Ex vivo expansion of retrovirally transduced primate CD34(+) cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Molecular Therapy, 18, 16331639.
  • Skorski, T. , Bellacosa, A. , Nieborowska- Skorska, M.N. , Majewski, M. , Martinez, R. , Choi, J.K. , Trotta, R. , Wlodarski, P. , Perrotti, D. , Chan, T.O. , Wasik, M.A. , Tsichlis, P.N. & Calabretta, B. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO Journal, 16, 61516161.
  • Smith, D.L. , Burthem, J. & Whetton, A.D. (2003) Molecular pathogenesis of chronic myeloid leukaemia. Expert Reviews in Molecular Medicine, 5, 127.
  • Stevens-Kroef, M. , Poppe, B. , van Zelderen-Bhola, S. , van den Berg, E. , van der Blij-Philipsen, M. , Geurts van Kessel, A. , Slater, R. , Hamers, G. , Michaux, L. , Speleman, F. & Hagemeijer, A. (2004) Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia, 18, 11081114.
  • Suzukawa, K. , Taki, T. , Abe, T. , Asoh, H. , Kamada, N. , Yokota, J. & Morishita, K. (1997) Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics, 42, 356360.
  • Valent, P. (2010) Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? European Journal of Clinical Investigation, 40, 918931.
  • Wetzler, M. , Talpaz, M. , Van Etten, R.A. , Hirsch-Ginsberg, C. , Beran, M. & Kuzrock, R. (1993) Subcellular localisation of Bcr, Abl and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. Journal of Clinical Investigation, 92, 19251939.
  • Wieser, R. (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene, 396, 346357.
  • Wimmer, K. , Vinatzer, U. , Zwirn, P. , Fonatsch, C. & Wieser, R. (1998) Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation. Biochemical and Biophysical Research Communications, 252, 691696.
  • Yuasa, H. , Oike, Y. , Iwama, A. , Nishikata, I. , Sugiyama, D. , Perkins, A. , Mucenski, M.L. , Suda, T. & Morishita, K. (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO Journal, 24, 19761987.